Optinose raises FY23 XCHANCE revenue view $64M-$70M from $62M-$68M

The Company expects XHANCE net revenues for the full year of 2023 to be between $64.0 to $70.0 million. Previously, the Company expected XHANCE net revenues for the full year of 2023 to be between $62.0 to $68.0 million. In addition, the Company continues to expect the full year 2023 XHANCE average net revenue per prescription to be approximately $200. The Company continues to expect total GAAP operating expenses for 2023 to be in the range of $88.0 to $93.0 million, of which the Company expects stock-based compensation to be approximately $6.0 million.